Bye-bye, Incivek: Sovaldi forces Vertex drug off hep C market

Just three years after nabbing the "fastest drug launch ever" award, Vertex ($VRTX) is discontinuing hepatitis C med Incivek on withering demand, it said in a recent letter to healthcare providers. For that, the Cambridge-based company has Sovaldi maker Gilead Sciences ($GILD)--owner of the new fastest drug launch ever--to thank. More